Skip to main content

The new standard in heart failure management

Non-invasive intracardiac pressure monitoring

Submit email to get updates

    A medical device for non-invasive monitoring of intracardiac pressure to help reduce re-hospitalizations due to heart failure and can lower mortality rates.

    Five sensor technologies

    Through a unique combination of visual, seismic, acoustic, electrocardiographic and pressure sensors, Acorai can ensure robustness across patient populations and recording environments.

    Machine learning analyzed

    Acorai’s machine learning engine leverages novel insights into pressure signals and noise segmentation, allowing for traceability and an understanding of what is driving the results.

    Patented and unique

    Acorai currently has 3 granted patent family applications with another 3 pending. The patents cover the unique hardware architecture and machine learning models that underly the device.

    The current standard procedure

    Today the most accurate monitoring method for early signs of relapse in heart failure is to do a right heart catheterization. This is often done on patients with previous heart issues to prevent recurring heart failure before rehospitalization is necessary.

    The right heart catheterization is performed by a cardiologist or pulmonologist with a team, room, and equipment specialized for this procedure. A long catheter is inserted from an incision and guided to the heart and pulmonary arteries and measurements are taken throughout the process.

    It is a common and low-risk procedure, but expensive and resource-intensive with unnecessary discomfort for the already fragile heart patient.

    Improved workflow with Acorai

    In the future, Acorai will be the standard procedure to measure Pulmonary Artery Pressure and is equally accurate to the right heart catheterization method.

    The patient does not have to suffer an invasive procedure and measurements can be taken more frequently. Measuring with Acorai only takes a few minutes and does not require a specialist team, room and other equipment. The device is simply held onto the patient’s chest while data is collected by the five different sensors, analyzed with machine learning and the result is displayed to the medical practitioner.

    Acorai can help decrease mortality rates for heart failure patients, reduce costs significantly and offer a better experience for the affected patient.

    Blog & News

    Stay up-to-date with our progress and the news from the industry

    Industry newsNew age of MedTechResearch

    Navigating the New Age of MedTech Sales & Marketing Series: Healthcare Equity

    This blog shares the combined sales and marketing experience of the Acorai team, and it will discuss what we have learned in an ever-changing MedTech and Life science industry. It aims to give other startups and established leaders insights into how the sector has changed and discuss critical themes and activities that will lead to continued product success.   If you…
    Matthew Mace
    September 19, 2022
    MonitoringRedefining Heart FailureStudies

    Mitigating Heart Failure Readmission

    Readmission Mitigation: A Summary In the prior editions of the "Redefining Heart Failure" blog series, we've explored the context of readmission statistics, their relevance for understanding the cause of admission, measures to prevent it, and the proven strategies available. If you would like to read them all before this part 5 on the mitigation measures, you can do so here:…
    Matthew Mace
    September 6, 2022
    MonitoringRedefining Heart FailureStudies

    Two Proven Strategies to Reduce Readmission

    Practices to Reduce Readmissions? In the prior edition of the "Redefining Heart Failure" blog series, we explored the context of readmission statistics, an understanding of the drivers of readmissions, and ways to reduce this burden. If you would like to read it before this part 3 on the factor which increases readmission, you can do so here: Pt1. Pt2.…
    Matthew Mace
    August 7, 2022
    The new standard in heart failure management

    On a mission

    Despite advances in the early detection and treatment of cardiovascular diseases, such as heart attacks and heart failures, costs are still high. 80% of all costs related to the treatment of heart failure are due to hospitalizations, and 75% of those hospitalizations are preventable.

    We understood that something had to be done, so we founded Acorai in 2019 with the vision of redefining the monitoring and treatment of patients with heart failure through new technology and artificial intelligence.

    We wanted to develop an AI-based medical device that could be the first non-invasive monitor of intracardiac pressure in the world. It could dramatically improve the health outcome for more than 30 million people suffering from heart failure around the world.

    “Can we leverage a novel combination of non-invasive sensor technologies with state-of-the-art machine learning methods to accurately detect impending heart failure?”

    After more than a year of research and development, we are now starting our first clinical trials to validate the technology with two of Europe’s leading hospitals.

    Support and funding


    Research, development & intellectual property


    Reimbursement & cost efficiency studies


    Commercialization & product development


    Follow us

    Submit your email to get updates

      Get in touch

      We are always happy to talk about our device and company. Reach out to us to discuss collaborations, investments, job opportunities or the latest medical research.